13 CHMP bad ansøgeren/ indehaveren af markedsføringstilladelsen om at redegøre for, hvorvidt ciprofloxacin kunne anses for at være en acceptabel mulighed til behandling eller profylakse hos patienter med svær neutropeni.
The CHMP asked the applicant/ MAH to discuss the extent to which ciprofloxacin could be viewed as an acceptable option in the treatment or prophylaxis in patients with severe neutropenia.